Tisagenlecleucel (Kymriah®) for the treatment of relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. Update July 2022

Rothschedl, E. and Wolf, S. (2022): Tisagenlecleucel (Kymriah®) for the treatment of relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. Update July 2022. Oncology Fact Sheet Nr. 88.

[thumbnail of Oncology Fact Sheet Nr.88_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
104kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WH Hemic and lymphatic systems
Language:	English
Series Name:	Oncology Fact Sheet Nr. 88
Deposited on:	25 Apr 2022 14:37
Last Modified:	26 Jul 2022 14:17

Repository Staff Only: item control page